Advanced Solid Tumors
Conditions
Keywords
Sirolimus for Injection (Albumin Bound)
Brief summary
The purpose of this study is to estimate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Sirolimus for Injection (Albumin Bound) in patients with solid malignancies.
Detailed description
This study will be conducted in two stages. Stage 1: To evaluate the safety and tolerability of Sirolimus for Injection (Albumin Bound) in patients with advanced tumors, determine the MTD and RP2D. The dose escalation scheme using the accelerated titration design for dose 1 and the rolling-six design for the remaining doses. Stage 2: To preliminarily assess the antitumor activity of Sirolimus for Injection (Albumin Bound). Patients will be assigned to different cohorts based on their tumor type.
Interventions
Sirolimus for Injection (Albumin Bound), intravenously, once a week, 28 days per cycle (three weeks-on and one week-off)
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-75 years (inclusive), no gender limitation. 2. Patients must have a histologically or cytologically confirmed advanced or metastatic tumor for which no effective standard therapy is available, or have failed or been intolerant to standard therapies. 3. At least one measurable lesion per RECIST version 1.1. 4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2. 5. Life expectancy of ≥3 months. 6. Suitable organs and hematopoietic function should be available. Laboratory tests during screening should meet the appropriate criteria. 7. Signed informed consent form.
Exclusion criteria
1. Prior anticancer treatment or participation in another clinical study within 4 weeks (or 5 half-lives of the treated drug, whichever is longer) prior to the first dose of study drugs. 2. Patients who have undergone major surgery within 4 weeks prior to starting study treatment, or who have not fully recovered from previous surgery. 3. Unresolved toxicities from prior therapy greater than Grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) (except alopecia or any other toxicity without safety risks as judged by the investigator). 4. History of serious cardiovascular disease. 5. Central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence that the patient's central nervous system metastasis or meningeal metastasis has not been controlled, and the investigator judges it to be unsuitable for inclusion. 6. Known prior hypersensitivity to study drugs or any component in their formulations. 7. Prior treatment with any mTOR inhibitor. 8. Has received a live or live-attenuated virus vaccine within 30 days prior to consent. 9. Uncontrollable active infection (CTCAE v5.0 ≥grade 2). 10. Use of strong inhibitors and inducers of CYP3A4 within 2 weeks prior to receiving the first dose of study drug and still need to continue using this class of drug. 11. History of autoimmune diseases, immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency, or organ transplant history. 12. HBsAg-positive with HBV viral load (VL) ≥1000 IU/mL; Hepatitis C Virus (HCV)-positive; Anti-treponema pallidum positive. 13. Women of child-bearing potential, or men whose partners are women of childbearing age, have not agree to use highly effective methods of contraception during dosing and for 6 months after study drug discontinuation; female patients has a positive serum pregnancy test within 7 days prior to receiving the first dose of study medication; lactating female. 14. Has history of other serious diseases judged by the investigator, which will threaten the safety of patients or interfere the study compliance, or other reasons are not suitable for participating in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events | Up to 3 years |
| Dose-Limiting Toxicities (Stage 1) | Cycle 1 (Up to 28 days) |
| Maximum tolerated dose (Stage 1) | Up to 1.5 years |
| Recommended phase 2 dose (Stage 1) | Up to 1.5 years |
| Overall response rate (Stage 2) | Up to 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Clearance (CL) | Day 1 of cycle 1 to Day 1 of cycle 4 (85 days) |
| Disease Control Rate | Up to 3 years |
| Duration of Response | Up to 3 years |
| Progression-free Survival | Up to 3 years |
| Area under the plasma concentration versus time curve (AUC) | Day 1 of cycle 1 to Day 1 of cycle 4 (85 days) |
| S6K phosphorylation level in blood samples | Up to 168 hours post dose |
| TSC1/2 status in tumor samples | Day 1 of cycle 1 |
| PTEN status in tumor samples | Day 1 of cycle 1 |
| PIK3CA status in tumor samples | Day 1 of cycle 1 |
| 4ebp-1 phosphorylation level in blood samples | Up to 168 hours post dose |
| Peak concentration (Cmax) | Day 1 of cycle 1 to Day 1 of cycle 4 (85 days) |
| Peak time (Tmax) | Day 1 of cycle 1 to Day 1 of cycle 4 (85 days) |
| Distribution volume (Vz) | Day 1 of cycle 1 to Day 1 of cycle 4 (85 days) |
| Elimination half-life (t1/2) | Day 1 of cycle 1 to Day 1 of cycle 4 (85 days) |
Countries
China
Contacts
Primary ContactXuekun Yao
Backup ContactYue Huang
Outcome results
None listed